Are matched unrelated donor transplants justified for AML in CR1?

This publication has 14 references indexed in Scilit:

• Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission
  Cancer, 2005
• Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.
  Blood, 2004
• Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome
  Blood, 2004
• Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation
  Annals of Hematology, 2004
• Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
  Blood, 2003
• HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen
  Blood, 2003
• Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
  Blood, 2003
• The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial
  British Journal of Haematology, 2002
• Haematopoietic cell transplantation as immunotherapy
  Nature, 2001
• A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group
  Blood, 2001